These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 373682)

  • 1. Interferon induction in mice by uniform salt forms of Shigella sonnei lipopolysaccharide and its components.
    Lugowski C; Błach-Olszewska Z; Cembrzyńska-Nowak M
    Arch Immunol Ther Exp (Warsz); 1978; 26(1-6):513-6. PubMed ID: 373682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The inductive immunosuppressive activity of the lipopolysaccharide from Shigella sonnei R forms].
    Borisova EV
    Mikrobiol Z; 1998; 60(3):63-9. PubMed ID: 9785801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The inductive immunosuppressive activity of the nonspecific lipopolysaccharide fraction of virulent Shigella sonnei].
    Borisova EV; Borisov VA
    Mikrobiol Z; 1997; 59(1):77-81. PubMed ID: 9172868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of Shigella sonnei phase I O-antigen.
    Kułakowska M; Romanowska E
    Arch Immunol Ther Exp (Warsz); 1981; 29(5):573-80. PubMed ID: 6181756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative studies on the immunologic properties of free endotoxin and lipopolysaccharide from Shigella sonnei.
    Kowalewska D; Romanowska E
    Arch Immunol Ther Exp (Warsz); 1977; 25(3):323-30. PubMed ID: 329799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antigenic and tolerogenic properties of Shigella sonnei lipopolysaccharide].
    Borisov VA; Gofman IL
    Mikrobiol Zh (1978); 1981; 43(1):74-7. PubMed ID: 7019631
    [No Abstract]   [Full Text] [Related]  

  • 8. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS).
    Morrison DC; Kline LF
    J Immunol; 1977 Jan; 118(1):362-8. PubMed ID: 318670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experimental model of high-dosage immunological tolerance to Shigella sonnei lipopolysaccharide].
    Borisov VA; Gofman IL
    Mikrobiol Zh (1978); 1980; 42(6):723-6. PubMed ID: 7007829
    [No Abstract]   [Full Text] [Related]  

  • 10. Strong adjuvanticity of bacterial lipopolysaccharides possessing the homopolysaccharides consisting of mannose as the O-specific polysaccharide chains.
    Kato N; Ohta M; Kido N; Naito S; Nakashima I; Nagase F; Yokochi T
    Med Microbiol Immunol; 1985; 174(1):1-14. PubMed ID: 3889573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lipopolysaccharides of Shigella sonnei].
    Borisova EV; Borisov VA
    Prikl Biokhim Mikrobiol; 2000; 36(5):597-602. PubMed ID: 11042887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies on adjuvanticity of Klebsiella O3 lipopolysaccharide and its lipid A and polysaccharide fractions.
    Kato N; Kido N; Ohta M; Naito S
    Immunology; 1985 Feb; 54(2):317-24. PubMed ID: 3881339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kinetics of endotoxin production in cultures of Shigella sonnei.
    Skurska Z; Blach-Olszewska Z; Romanowska E; Mulczyk M
    Arch Immunol Ther Exp (Warsz); 1972; 20(4):453-9. PubMed ID: 4562365
    [No Abstract]   [Full Text] [Related]  

  • 14. [The biological activity of a lipopolysaccharide from Ralstonia solanacearum ICMP 7859 and of its modified derivative].
    Varbanets LD; Seĭfullina II; Rybalko SL; Diadiun ST; Brovarskaia OS
    Mikrobiol Z; 1998; 60(4):80-7. PubMed ID: 9859644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of the structural components of bacterial lipopolysaccharide in its inductive immunosuppressive activity].
    Borisova EV
    Mikrobiol Z; 1999; 61(6):36-41. PubMed ID: 10707531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes in antigenic properties of lipopolysaccharides of Shigella sonnei phase I having lost the virulence due to transposon integration into the invasiveness plasmid PSS120].
    Nikolaeva AI; Nastichkin IA; Romanova IuM; Belova TS; Bondarenko VM; Kabanova EA; Kondrat'eva TK
    Mol Gen Mikrobiol Virusol; 1990 Aug; (8):15-8. PubMed ID: 2172809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The immunobiological properties of the lipopolysaccharides of bacteria in the genus Shigella with contrasting virulence and their chemically modified analogs].
    Borisova EV
    Mikrobiol Z; 1999; 61(4):64-71. PubMed ID: 10565153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on Shigella sonnei phase I and phase II lipopolysaccharides.
    Romanowska E; Lugowski C; Mulczyk M
    J Hyg Epidemiol Microbiol Immunol; 1974; 18(4):391-6. PubMed ID: 4616051
    [No Abstract]   [Full Text] [Related]  

  • 19. L-rhamnose inhibits proliferation of murine splenocytes by the lipopolysaccharide and polysaccharide moiety of Shigella dysenteriae type 1 lipopolysaccharide.
    Biswas T; Roy S; Banerjee KK
    Immunology; 1995 Feb; 84(2):322-5. PubMed ID: 7751010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of detoxification processes on the interferon-inducing activity of bacterial endotoxins.
    Sourek J; Jandejsek J; Levin J
    Acta Microbiol Hung; 1989; 36(4):439-43. PubMed ID: 2484274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.